Clinical Trials
Novel Chemotherapy
Thoracic Oncology

Get to Know Dr. Mark A. Socinski

Medical oncologist Dr. Mark Socinski is recognized as one of America’s leading lung cancer specialists, earning the acclaim for his work in the development of novel, personalized treatment stemming from molecular biomarkers.

Socinski joined AdventHealth Cancer Institute in 2016 after serving as professor of medicine and cardiovascular surgery at the University of Pittsburgh Medical Center.

He worked previously as a professor of medicine at the University of North Carolina and as co-chair of the National Cancer Institute Thoracic Malignancy Steering Committee.

Socinski also specializes in the treatment of pleural mesothelioma, working closely at AdventHealth with thoracic surgeon Dr. Marcelo DaSilva, head of the Mesothelioma International Treatment Program.

Through his research efforts with lung cancer, Socinski is heavily involved in novel clinical trials that offer up cutting-edge treatment advancements.

Socinski was listed as one of the top 10 lung cancer specialists in the U.S. by Expertscape, an online platform that identifies physicians of excellence in various fields.

Specialties of Dr. Mark A. Socinski

  • Advanced non-small cell lung cancer
  • Small cell lung cancer
  • Pleural mesothelioma
  • Chemotherapy
  • Immunotherapy
  • Molecular biomarkers

Dr. Mark A. Socinski’s Experience and Medical Education

  • AdventHealth Cancer Institute
  • University of Pittsburgh Medical Center
  • University of North Carolina Medical Center
  • Dana-Farber Cancer Institute (Fellowship)
  • Harvard Medical School, Beth Israel Hospital (Fellowship and residency)
  • University of Vermont College of Medicine (M.D.)

Awards and Certifications

  • American Board of Internal Medicine
  • Florida State Medical License
  • America’s Top Doctors
  • U.S. Lung Cancer Specialists, Expertscape

Publications of Dr. Mark A. Socinski

  • Le, X. et al. (2022, March 1). Poziotinib in Non-Small Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. Journal of Clinical Oncology.
  • Nogami, N. et al. (2022, February). Impower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. Journal of Thoracic Oncology.
  • Camidge, D.R. et al. (2021, June). Crizotinib in Patients With MET-Amplified NSCLC. Journal of Thoracic Oncology.
  • Judd, J. et al. (2021, December 3). Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Molecular Cancer Therapeutics.